• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.25% Nasdaq Up0.65%

    More On PXSLY



    News & Info


    Analyst Coverage


    • Major Holders
    • Insider Transactions
    • Insider Roster


    Pharmaxis Ltd. (PXSLY)

    -Other OTC
    3.04 0.00(0.00%) N/A
    ProfileGet Profile for:
    Pharmaxis Ltd.
    20 Rodborough Road
    Frenchs Forest, NSW 2086
    Australia - Map
    Phone: 61 2 9454 7200
    Fax: 61 2 9451 3622
    Website: http://www.pharmaxis.com.au

    Index Membership:N/A
    Full Time Employees:61

    Business Summary 

    Pharmaxis Ltd, a specialty pharmaceutical company, engages in the research, development, and commercialization of human healthcare products for the treatment and management of chronic diseases worldwide. Its product candidates are used for the treatment of lung diseases, such as cystic fibrosis, bronchiectasis, asthma, and chronic obstructive pulmonary disease (COPD); and inflammatory and fibrotic diseases, such as nonalcoholic steatohepatitis and pulmonary fibrosis. The company offers Aridol lung function test, which is designed to assist physicians in the assessment of asthma by identifying and measuring airway hyperresponsiveness; and Bronchitol, a drug designed to reduce the amount of mucus build-up in the lungs of patients suffering from chronic respiratory conditions. Its early stage product development pipeline includes PXS-4728A, a SSAO/VAP-1 inhibitor for the treatment of inflammation; orbital dry powder inhaler that delivers drug doses to the lungs; Lysyl Oxidase Like 2 inhibitors for the treatment of fibrosis; and PXS64/25 targeting lung fibrosis; and ASM8 targeting severe asthma. The company has research collaboration with Synairgen plc to develop a selective inhibitor to the lysyl oxidase type 2 enzyme to treat idiopathic pulmonary fibrosis, a lung disease. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Pharmaxis Ltd.

    Key Executives 
    Mr. Gary Jonathan Phillips BPharm, MBA, 55
    Chief Exec. Officer, Director and Member of Disclosure Committee
    Mr. David Morris McGarvey BA, CA, CPA, 60
    Chief Financial Officer, Company Sec. and Member of Disclosure Committee
    Mr. Wolfgang G. Jarolimek B.Sc. Ph.D., 52
    Head of Drug Discovery
    Dr. Brett Charlton MBBS Ph.D., 60
    Medical Director and Member of Disclosure Committee
    Ms. Kristen Morgan BSc,PGDipBusAdmin,MMedSc,
    Exec. Officer
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.